Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
ACTIVE_NOT_RECRUITING
Status
Conditions
- Hematologic and Lymphocytic Disorder
- Hematopoietic and Lymphoid System Neoplasm
Interventions
- DRUG: Placebo Administration
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
- BIOLOGICAL: Ustekinumab
Sponsor
Fred Hutchinson Cancer Center